查看完整行情页>>

|

货币单位:美元(USD)

居里

Curis, Inc. (cris)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Mark W. Noel Mark W. Noel is VP-Technology Management & Intellectual Property at Curis, Inc. Mr. Noel previously occupied the position of Vice President-Customer Relations at Gene Logic, Inc., Director-Regulatory Affairs Department at Gist-Brocades NV and Deputy Director at National Cancer Institute. Mr. Noel received an undergraduate degree from the University of Maryland.
Jonathan B. Zung Jonathan B. Zung is Chief Development Officer of Curis, Inc. In the past he occupied the position of VP & Head-Global Clinical Sciences & Operations at UCB SA, Chief Development Officer at Evelo Biosciences, Inc., President at Clintrax Global, Inc., Group President-Clinical Development at Labcorp Drug Development, Inc., President-Sponsor & CRO Programs at WIRB- Copernicus Group, Inc. and Chairman of Clinical Data Interchange Standards Consortium, Inc. Dr. Zung received a doctorate from Emory University and an undergraduate degree from Florida Institute of Technology, Inc.
Reinhard von Roemeling Currently, Reinhard von Roemeling is Senior Vice President-Clinical Development at Curis, Inc. In the past he occupied the position of Global Head-Research & Development at HUYA Bioscience International LLC. He received a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Kimberly Steinmann Presently, Kimberly Steinmann holds the position of Vice President-Clinical Development at Curis, Inc. Dr. Steinmann previously held the position of Executive Director-Medical at Grifols, Inc. Dr. Steinmann received an undergraduate degree and a doctorate from St. Louis University.
Robert E. Martell Founder of Epi-Cure Pharmaceuticals, Inc., Robert E. Martell presently is Chief Scientific Officer at Curis, Inc. Dr. Martell is also on the board of Indaptus Therapeutics, Inc. and Member of American Society of Clinical Oncology, Inc., Member of American Association for Cancer Research and Professor at Tufts University School of Medicine. Robert E. Martell previously was Director-Oncology Global Clinical Research at Bristol Myers Squibb Co. and Chief Medical Officer & Vice President at Mirati Therapeutics, Inc. (a subsidiary of Bristol Myers Squibb Co.), President & Director at Epi-Cure Pharmaceuticals, Inc., Chief Medical Officer at Tesaro, Inc., Deputy Director-Pharmaceutical Division at Bayer Corp., Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Director-Neely Center at Clinical Cancer Research, Associate Chief-Division of Hematology/Oncology at Tufts Medical Center, Inc., Associate Professor at Tufts Medical Center, Inc., Assistant Professor at Duke University Medical Center and Assistant Clinical Professor at Yale School of Medicine. Robert E. Martell received an undergraduate degree from Kalamazoo College, a doctorate from the University of Michigan and a doctorate from Wayne State University (Michigan).
Martyn D. Greenacre Martyn D. Greenacre is a businessperson who has been at the helm of 8 different companies. Presently, he holds the position of Chairman at Curis, Inc. and Chairman at Life Mist Technologies, Inc. Mr. Greenacre is also on the board of Formula Pharmaceuticals, Inc. In his past career Mr. Greenacre occupied the position of Chairman for Acusphere, Inc., Chairman at Life Mist LLC, Senior Advisor at Arsenal Capital Management LP, Chairman of Beijing Med-Pharm Corp., Chairman of BMP Sunstone Corp., President & Chief Executive Officer at Zynaxis, Inc., Chief Executive Officer & Director at Delsys Pharmaceutical Corp., Member-Executive Committee at Applera Corp. and Director & Chairman-European Operations at Smithkline Beecham Pharmaceuticals (India) Ltd. He received an MBA from Harvard Business School and an undergraduate degree from Harvard College.
James E. Dentzer Presently, James E. Dentzer occupies the position of President, Chief Executive Officer & Director at Curis, Inc. He is also on the board of Imunon, Inc. He previously held the position of Chief Financial Officer of Amicus Therapeutics, Inc., Controller of Biogen, Inc., Chief Financial Officer for Dicerna Pharmaceuticals, Inc., Chief Financial Officer at Valeritas, Inc. and Chief Financial Officer-DuPont Flooring Systems at EIDP, Inc. James E. Dentzer received an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
Marc Rubin Marc Rubin is a businessperson who has been at the helm of 5 different companies is on the board of Curis, Inc., Galectin Therapeutics, Inc. (former Chairman), Soricimed Biopharma, Inc. and The Rogosin Institute, Inc. He previously was Director at Titan Pharmaceuticals, Inc., President & Chief Executive Officer for Titan Pharmaceuticals, Inc., Senior Vice President-Global Clinical Pharmacology at GSK Plc, Chairman for Schering Berlin, Inc., President of Berlex Pharmaceuticals, Inc., Head-Global Research & Development at Bayer Pharma AG, Head-Global Research & Development at Bayer Schering Pharma AG and Member-Executive Committee at Bayer HealthCare. Marc Rubin received a doctorate from Weill Cornell Medical College.
John A. Hohneker John A. Hohneker is on the board of Curis, Inc. and 4 other companies. In the past he held the position of President & Chief Executive Officer of Anokion SA and President, Chief Executive Officer & Director at Kanyos Bio, Inc. (a subsidiary of Anokion SA), SVP & Global Head-Development & Immunology at Novartis AG and Head-Research & Development at FORMA Therapeutics, Inc. Dr. Hohneker received an undergraduate degree from Gettysburg College, a doctorate from the University of Medicine & Dentistry of New Jersey and a doctorate from Robert Wood Johnson Medical School.
Kenneth I. Kaitin Kenneth I. Kaitin is on the board of Curis, Inc., Bio-Tree Systems, Inc., Centerphase Solutions, Inc. and QCDx LLC. Dr. Kaitin previously held the position of Director-Drug Development Study at Tufts Center for the Study of Drug Development, President at Drug Information Association and Professor at Tufts University School of Medicine. Dr. Kaitin received a doctorate and a graduate degree from the University of Rochester and an undergraduate degree from Cornell University.